波士顿科学公司宣布达成收购Penumbra的协议-动脉网

Boston Scientific announces agreement to acquire Penumbra, Inc.

波士顿科学等信源发布 2026-01-15 20:07



可切换为仅中文







Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases

收购将扩大波士顿科学的心血管产品组合，并进一步应对日益增多的血管疾病问题。

Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies

提供进入机械血栓切除术和神经血管领域的规模化切入点，具有关键的战略邻接性

Conference call at

电话会议于

8:00 a.m. ET

东部时间上午8:00

to discuss details of the transaction

讨论交易的细节

MARLBOROUGH, Mass.

马尔伯勒，马萨诸塞州

and

和

ALAMEDA, Calif.

阿拉米达，加利福尼亚州

，

Jan. 15, 2026

2026年1月15日

PRNewswire

美通社

/ -- Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., (NYSE: PEN) today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at

波士顿科学公司（纽约证券交易所代码：BSX）和Penumbra公司（纽约证券交易所代码：PEN）今天宣布，两家公司已达成一项最终协议，根据该协议，波士顿科学公司将通过现金加股票交易收购Penumbra公司，该交易对Penumbra的估值为

$374

374美元

per share, reflecting an enterprise value of approximately

每股，企业价值约为

$14.5 billion

145亿美元

。

我

'Penumbra is a well-established company with an experienced, high-performing team and this acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space,' said

“Penumbra是一家拥有经验丰富、高效团队的成熟公司，此次收购为波士顿科学提供了进入血管领域内新兴、快速增长细分市场的机会，”

Mike Mahoney

迈克·马奥尼

, chairman and chief executive officer, Boston Scientific. 'I'm thrilled to combine the talents and shared values of our teams – including welcoming Penumbra's chairman and chief executive officer,

，董事长兼首席执行官，波士顿科学公司。 “我非常高兴能够将我们团队的才华和共同价值观结合起来——包括欢迎Penumbra的董事长兼首席执行官，

Adam Elsesser

亚当·埃尔塞瑟

, to our board of directors upon close. The addition of Penumbra can expand access for these novel technologies to more patients and customers around the world, further enhancing our revenue and margins over time with proven offerings that have a history of growth and innovation.'

“，在交易结束时加入我们的董事会。增加Penumbra可以使这些新颖的技术触及到世界各地更多的患者和客户，随着时间的推移，通过经过验证的产品进一步提高我们的收入和利润，这些产品有着增长和创新的历史。”

Cardiovascular diseases are the leading cause of death globally

心血管疾病是全球死亡的主要原因。

二

and include disorders of the heart and blood vessels that can restrict blood flow and increase the risk of clots throughout the body. To address the escalating prevalence of these complex diseases, Penumbra has developed a comprehensive portfolio that includes differentiated devices to treat conditions such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms..

并包括可能限制血流并增加全身凝血风险的心脏和血管疾病。为应对这些复杂疾病日益增长的发病率，Penumbra 开发了一个全面的产品组合，其中包括用于治疗肺栓塞、中风、深静脉血栓、急性肢体缺血、心脏病发作和动脉瘤等疾病的差异化设备。

Penumbra offers innovative mechanical thrombectomy products for use in peripheral vascular procedures to remove blood clots causing blockages in arterial, venous and pulmonary vessels, including the Lightning Bolt

Penumbra提供用于外周血管手术的创新机械血栓切除产品，以去除导致动脉、静脉和肺血管阻塞的血凝块，其中包括Lightning Bolt。

and Lightning Flash

和闪电

computer assisted vacuum thrombectomy (CAVT™) systems. The company's vascular portfolio also includes a minimally invasive peripheral embolization system, which is designed to stop blood flow to control hemorrhaging and bleeding or to close blood vessels.

计算机辅助真空血栓切除术（CAVT™）系统。该公司的血管产品组合还包括一种微创的外周栓塞系统，旨在通过停止血流来控制出血和止血，或关闭血管。

Neurovascular offerings from Penumbra currently include differentiated solutions for access, stroke revascularization and neuro embolization. The company is continuing to innovate in these areas and add meaningful clinical evidence to support expanded access for more patients worldwide.

Penumbra的神经血管产品目前包括用于通路、卒中血运重建和神经栓塞的差异化解决方案。该公司继续在这些领域进行创新，并增加有意义的临床证据，以支持全球更多患者获得扩展的治疗机会。

'Our decades-long development of therapies for challenging medical conditions has focused on deep innovation for complex diseases so that we can offer physicians novel solutions to transform patient care,' said

“我们数十年来针对棘手医疗状况的疗法开发，一直专注于复杂疾病的深度创新，从而为医生提供改变患者护理的全新解决方案，”表示

Adam Elsesser

亚当·埃尔塞瑟

. 'I am grateful for the amazing people who have contributed to this work and look forward to uniting our efforts and shared values as we come together with Boston Scientific.'

“我感谢为这项工作做出贡献的出色人员，并期待在我们与波士顿科学公司携手合作时，团结我们的努力和共同的价值观。”

Penumbra expects to deliver fourth quarter reported revenue growth in the range of approximately 21.4% - 22.0% and full year 2025 reported revenue of approximately

Penumbra预计第四季度报告的收入增长范围约为21.4% - 22.0%，2025年全年报告的收入约为

$1.4 billion

14亿美元

, representing growth in the range of approximately 17.3% - 17.5% over the prior fiscal year.

，较上一财政年度增长约17.3% - 17.5%。

iii

Penumbra continues to advance its technologies with a multi-year research and development plan and ongoing clinical programs.

Penumbra继续通过多年的研发计划和持续的临床项目来推进其技术。

Under the terms of the agreement, which has been approved by the board of directors of each company, the transaction values each Penumbra share at

根据协议条款，该协议已获各公司董事会批准，交易对彭布罗克每股的估值为

$374

374美元

, with Penumbra stockholders having the right to elect to receive

，拥有选择接收权利的半影股东

$374

374美元

in cash or 3.8721 shares of Boston Scientific common stock (valued at

现金或3.8721股波士顿科学普通股（价值

$374

374美元

based on the volume weighted average price of Boston Scientific common stock over the last 10 trading days, as of

基于过去10个交易日波士顿科学公司普通股的成交量加权平均价格，截至

January 13, 2026

2026年1月13日

), subject to proration, so that the total transaction consideration is paid approximately 73% in cash and approximately 27% in shares of Boston Scientific common stock.

)，须按比例分配，使得总交易对价中约73%以现金支付，约27%以波士顿科学公司普通股股票支付。

Adam Elsesser

亚当·埃尔塞瑟

has indicated that he will elect to receive Boston Scientific shares for all his Penumbra shares.

已表示他将选择用他所有的Penumbra股份来换取波士顿科学公司的股份。

Boston Scientific expects to finance the approximately

波士顿科学公司预计将会为大约...融资

$11 billion

110亿美元

cash portion of the transaction consideration with a combination of cash on hand and new debt. The transaction is expected to be

交易对价的现金部分将通过手头现金和新债务的组合支付。该交易预计将会

$0.06

0.06美元

-0.08 dilutive to adjusted earnings per share for Boston Scientific in the first full year following the close of the acquisition, neutral to slightly accretive in the second year and more accretive thereafter. The impact to GAAP earnings per share is expected to be dilutive in the first full year following the close, and less dilutive or increasingly accretive thereafter, as the case may be, due to amortization expense and acquisition-related net charges. .

-0.08 稀释波士顿科学公司在收购完成后的第一个完整财年的调整后每股收益，第二年中性到略微增值，此后更加增值。对按照一般公认会计原则计算的每股收益的影响预计在收购完成后的第一个完整财年为稀释性，此后由于摊销费用和与收购相关的净费用，可能会变得不那么稀释或越来越增值。

The transaction is expected to be completed in 2026, subject to receipt of Penumbra's stockholder approval and the satisfaction of other customary closing conditions.

该交易预计将在2026年完成，但需获得Penumbra股东的批准，并满足其他惯例的交割条件。

Boston Scientific will be discussing this announcement on a conference call today at

波士顿科学公司将在今天举行的电话会议上讨论此公告

8:00 a.m. ET

东部时间上午8:00

, which can be accessed on the

，可以在以下位置访问：

Events and Presentations

事件与展示

section of the Boston Scientific investor relations website along with additional information about this transaction.

波士顿科学公司投资者关系网站的部分内容，以及有关此交易的更多信息。

Allen Overy Shearman

安理国际律师事务所

& Sterling LLP and Arnold & Porter Kaye Scholer LLP are serving as legal advisors to Boston Scientific.

& Sterling LLP 和 Arnold & Porter Kaye Scholer LLP 担任波士顿科学公司的法律顾问。

Perella Weinberg Partners is serving as exclusive financial advisor to Penumbra and

佩雷拉·温伯格合伙人公司担任佩努姆布拉的独家财务顾问和

Davis Polk

戴维斯·波尔克律师事务所

& Wardwell LLP is serving as legal advisor.

&Wardwell LLP担任法律顾问。

About Boston Scientific

关于波士顿科学公司

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.

波士顿科学通过创新的医疗技术改善全球患者的健康，从而改变生活。作为拥有45年以上历史的全球医疗技术领导者，我们通过提供广泛满足患者未满足需求的高性能解决方案，推动生命科学的发展，并降低医疗成本。

Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at .

我们的设备和疗法产品组合帮助医生诊断和治疗复杂的心血管、呼吸系统、消化系统、肿瘤学、神经学和泌尿系统疾病及症状。欲了解更多信息，请访问。

www.bostonscientific.com

and follow us on

关注我们

LinkedIn.

领英。

About Penumbra

关于半影

Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity.

Penumbra, Inc. 是世界领先的血栓切除公司，专注于为缺血性中风、静脉血栓栓塞（如肺栓塞）和急性肢体缺血等具有挑战性的医疗状况开发最具创新性的技术。我们广泛的产品组合包括计算机辅助真空血栓切除术 (CAVT)，专注于以快速、安全和简便的方式从头到脚清除血栓。

By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit .

通过开创这些创新，我们为100多个国家的医疗保健提供者、医院和诊所提供了支持，致力于改善患者的治疗效果和生活质量。欲了解更多信息，请访问。

www.penumbrainc.com

and connect on

连接到

Instagram

，

领英

, and

，以及

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like 'anticipate,' 'expect,' 'project,' 'believe,' 'plan,' 'estimate,' 'intend' and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the financial and business impact of the transaction and anticipated benefits of the transaction, the closing of the transaction and the timing thereof, business plans and strategy, product launches and product performance and impact, clinical programs, and expected financial results. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. .

本新闻稿包含1933年《证券法》第27A条和1934年《证券交易法》第21E条所指的前瞻性陈述。前瞻性陈述可以通过诸如“预期”、“预计”、“计划”、“相信”、“规划”、“估计”、“打算”等类似词语加以识别。这些前瞻性陈述基于我们根据当时可获得的信息所做出的信念、假设和估计，并非对未来事件或表现的保证。这些前瞻性陈述包括但不限于关于交易的财务和业务影响及预期收益、交易的完成及其时间安排、业务计划与战略、产品发布及产品性能与影响、临床项目以及预期财务结果的陈述。如果我们的基本假设被证明不正确，或者某些风险或不确定性成为现实，实际结果可能与我们在前瞻性陈述中表达或暗示的预期和预测存在重大差异。在某些情况下，这些因素已经影响，并且未来（连同其他因素）可能会影响我们实施商业战略的能力，并导致实际结果与本新闻稿中陈述的内容有重大差异。因此，读者被提醒不要过度依赖我们的任何前瞻性陈述。

Factors that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions, including the ability to achieve the anticipated benefits of the proposed transaction and successfully integrate Penumbra's operations; business disruptions (including disruptions in relationships with employees, customers or suppliers) following the announcement and/or closing of the proposed transaction; demographic trends; intellectual property; litigation; financial market conditions; future business decisions made by us and our competitors; the conditions to the completion of the proposed transaction, including the receipt of the required regulatory approvals and clearances, may not be satisfied at all or in a timely manner; and the closing of the proposed transaction may not occur or may be delayed. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect each of Boston Scientific's and Penumbra's businesses and future operations, see Part I, Item 1A – .

可能导致此类差异的因素包括但不限于：经济状况，包括外汇波动的影响；未来的美国和全球政治、竞争、报销和监管环境，包括不断变化的贸易和关税政策；地缘政治事件；制造、分销和供应链中断及成本增加；网络安全事件引发的中断；公共卫生紧急事件或极端天气及其他与气候变化相关的事件引发的中断；劳动力短缺和劳动力成本上升；正在进行和未来临床试验及市场研究结果的变化；新产品推出；预期手术量；收购的完成与整合，包括实现拟议交易预期收益的能力以及成功整合Penumbra运营的能力；拟议交易宣布和/或完成后业务中断（包括与员工、客户或供应商关系的中断）；人口趋势；知识产权；诉讼；金融市场状况；我们及竞争对手做出的未来商业决策；拟议交易完成的条件，包括获得所需的监管批准和许可，可能无法全部满足或及时满足；拟议交易的完成可能不会发生或可能延迟。所有这些因素都难以或无法准确预测，其中许多因素是我们无法控制的。有关可能影响Boston Scientific和Penumbra业务及未来运营的这些及其他重要风险和不确定性的进一步列表和描述，请参见第I部分，第1A项 – 。

Risk Factors

风险因素

in Boston Scientific's and Penumbra's respective most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which may be updated in Part II, Item 1A –

在波士顿科学公司和Penumbra最近各自向证券交易委员会提交的10-K表格年度报告中，该内容可能在第二部分第1A项中更新。

Risk Factors

风险因素

in Quarterly Reports on Form 10-Q each company has filed or will file hereafter. Boston Scientific and Penumbra each disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document..

在每家公司已提交或将在以后提交的10-Q季度报告中。波士顿科学公司和Penumbra均否认有任何意图或义务公开更新或修改任何前瞻性声明，以反映我们预期中的任何变化或作为这些预期基础的事件、条件或情况的变化，或者可能影响实际结果与前瞻性声明中包含的结果不同的可能性，除非法律要求。此警示声明适用于本文件中包含的所有前瞻性声明。

Important Information and Where to Find It

重要信息及其查找位置

In connection with the proposed transaction, Boston Scientific will file with the Securities and Exchange Commission (the '

与此拟议交易相关，波士顿科学公司将向证券交易委员会（提交文件。

SEC

证券交易委员会

') a registration statement on Form S-4 that will include a proxy statement/prospectus (the '

`) 一份包含代理声明/招股说明书的 S-4 表格注册声明（`

Proxy Statement/Prospectus

代理声明/招股说明书

') for the stockholders of Penumbra, and Penumbra will mail the Proxy Statement/Prospectus to its stockholders and file other documents regarding the proposed transaction with the SEC. This communication is not a substitute for any proxy statement, registration statement, proxy statement/prospectus or other documents Boston Scientific and/or Penumbra may file with the SEC in connection with the proposed transaction.

`)，并将向其股东邮寄委托书/招股说明书，并就该拟议交易向美国证券交易委员会提交其他文件。本通讯并非波士顿科学公司和/或Penumbra可能就该拟议交易向美国证券交易委员会提交的任何委托书、注册声明、委托书/招股说明书或其他文件的替代品。`

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE, ANY AMENDMENTS OR SUPPLEMENTS TO THE PROXY STATEMENT/PROSPECTUS, AND OTHER DOCUMENTS FILED BY .

投资者和证券持有人被敦促在代理声明/招股说明书可供使用时，仔细并完整阅读该文件、任何对代理声明/招股说明书的修订或补充，以及提交的其他文件。

BOSTON

波士顿

SCIENTIFIC OR PENUMBRA WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the Proxy Statement/Prospectus and other documents filed with the SEC by Boston Scientific and/or Penumbra through the website maintained by the SEC at .

波士顿科学公司或半影公司就拟议交易与美国证券交易委员会（SEC）提交的文件，因为这些文件将包含重要信息。投资者和证券持有人可以通过美国证券交易委员会维护的网站免费获取波士顿科学公司和/或半影公司提交的委托书/招股说明书及其他文件。

www.sec.gov

. Security holders will also be able to obtain free copies of the documents filed by Boston Scientific with the SEC on Boston Scientific's website at

. 证券持有者还将能够在波士顿科学公司的网站上免费获取波士顿科学公司向美国证券交易委员会提交的文件副本，网址为

investors.bostonscientific.com

投资者.波士顿科学.com

or by contacting Boston Scientific Investor Relations at

或通过联系波士顿科学投资者关系部门

BSXInvestorRelations@bsci.com

or by calling 508-683-4479. Security holders will also be able to obtain free copies of the documents filed by Penumbra with the SEC on Penumbra's website at

或通过拨打508-683-4479。安全持有者还可以在Penumbra的网站上免费获取Penumbra向SEC提交的文件副本，网址为

https://www.penumbrainc.com/investors/sec-filings/

or by contacting Penumbra Investor Relations at

或通过联系Penumbra投资者关系部门

investors@penumbrainc.com

投资者@佩努姆布拉公司.com

。

No Offer or Solicitation

无提供或招揽

This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

本通讯仅供参考，无意且不构成对任何证券的认购、购买或出售的要约，也不构成对认购、购买或出售的要约的招揽或邀请，亦不构成在任何司法管辖区就拟议交易或相关事项征求任何投票或批准，也不得在违反适用法律的情况下在任何司法管辖区进行证券的销售、发行或转让。

No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law..

除非根据经修订的1933年《证券法》第10节的要求通过符合规定的招股说明书，否则不得进行证券发售，并且必须遵守适用法律的其他规定。

Participants in the Solicitation

征求活动的参与者

Boston Scientific

波士顿科学公司

，

Penumbra and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Penumbra's stockholders in connection with the proposed transaction. Information regarding Boston Scientific's directors and executive officers, including a description of their respective direct or indirect interests, by security holdings or otherwise, will be set forth in the Joint Proxy Statement/Prospectus and other relevant materials when they are filed with the SEC.

Penumbra 以及其某些董事和高级管理人员可能会被视为在拟议交易中向 Penumbra 股东征求代理投票的参与者。有关 Boston Scientific 的董事和高级管理人员的信息，包括他们各自通过证券持有或其他方式形成的直接或间接利益的描述，将在提交给美国证券交易委员会 (SEC) 的联合代理声明/招股说明书中以及其他相关材料中列出。

These documents (when available) may be obtained free of charge from the SEC's website at .

这些文件（如果有的话）可以免费从美国证券交易委员会的网站上获得。

www.sec.gov

or by accessing the Investor Relations section of the Boston Scientific website at

或通过访问波士顿科学网站的投资者关系部分

investors.bostonscientific.com

投资者.bostonscientific.com

. Information regarding the Boston Scientific's directors and executive officers is contained in the sections entitled '

. 有关波士顿科学公司董事和高级管理人员的信息包含在题为“

Election of Directors

董事选举

' and '

' 且 '

Securities Ownership of Director and Executive Officers

董事和高级管理人员的证券所有权

' included in Boston Scientific's proxy statement for its 2025 annual meeting of stockholders, which was filed with the SEC on

包含在波士顿科学公司为其2025年股东大会提交给美国证券交易委员会的委托声明中，

March 19, 2025

2025年3月19日

(and which is available at

（并且可以在以下位置获取：

https://www.sec.gov/ix?doc=/Archives/edgar/data/885725/000088572525000017/bsx-20250319.htm

), in the section entitled '

），在标题为“

Directors, Executive Officers and Corporate Governance

董事、高级管理人员及公司治理

' included in Boston Scientific's Annual Report on Form 10-K for the year ended

包含在波士顿科学公司截至年度的10-K表格年报中

December 31, 2024

2024年12月31日

, which was filed with the SEC on

，已于向美国证券交易委员会（SEC）提交

February 18, 2025

2025年2月18日

(and which is available at

（并且可以在以下位置获取：

https://www.sec.gov/ix?doc=/Archives/edgar/data/885725/000088572525000011/bsx-20241231.htm

), in Boston Scientific's Form 8-K filed on

），在波士顿科学公司于

April 23, 2025

2025年4月23日

(and which is available at

（并且可在以下位置获取：

https://www.sec.gov/ix?doc=/Archives/edgar/data/885725/000088572525000024/bsx-20250418.htm

), in Boston Scientific's Form 8-K filed on

），在波士顿科学公司于

September 4, 2025

2025年9月4日

(and which is available at

（并且可在以下位置获取：

https://www.sec.gov/ix?doc=/Archives/edgar/data/885725/000088572525000043/bsx-20250829.htm

), and in the Boston Scientific's Form 8-K filed on

），并在波士顿科学公司提交的 8-K 表格中

October 23, 2025

2025年10月23日

(and which is available at

（并且可以在以下位置获取：

https://www.sec.gov/ix?doc=/Archives/edgar/data/885725/000088572525000048/bsx-20251022.htm

). To the extent holdings of Boston Scientific securities by the directors and executive officers of Boston Scientific have changed from the amounts of securities of Boston Scientific held by such persons as reflected therein, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC.

). 波士顿科学公司的董事和高级管理人员所持有的波士顿科学公司证券的变动，如与其中反映的此类人员持有的波士顿科学公司证券数量有所不同，这些变动已或将在向美国证券交易委员会提交的表格4的所有权变动声明中反映。

Information regarding Penumbra's directors and executive officers is contained in the sections entitled .

有关Penumbra董事和高级管理人员的信息包含在以下部分中。

Proposal No. 1: Election of Directors

提案一：董事选举

', '

Information Regarding the Board of Directors and Corporate Governance

关于董事会和公司治理的信息

', and '

', 以及 '

Other Information Related to Penumbra, Its Directors and Executive Officers

与Penumbra及其董事和高级管理人员有关的其他信息

' included in Penumbra's proxy statement for its 2025 annual meeting of stockholders, filed with the SEC on

包含在Penumbra向SEC提交的2025年股东大会的委托书声明中，

April 16, 2025

2025年4月16日

(and which is available at

（并且可以在以下位置获取：

https://www.sec.gov/ix?doc=/Archives/edgar/data/1321732/000132173225000074/pen-20250416.htm

), in the section entitled '

），在标题为‘

Directors, Executive Officers and Corporate Governance

董事、高级管理人员和公司治理

' included in Penumbra's Annual Report on Form 10-K for the year ended

包含在Penumbra截至年度的10-K表格年报中

December 31, 2024

2024年12月31日

, which was filed with the SEC on

，已提交给美国证券交易委员会

February 18, 2025

2025年2月18日

(and which is available at

（并且可在以下位置获取：

https://www.sec.gov/ix?doc=/Archives/edgar/data/1321732/000132173225000012/pen-20241231.htm

and in Penumbra's Form 8-K filed on

并在半影的8-K表格中提交的文件上

August 27, 2025

2025年8月27日

(

and which is available at

并且可以在以下位置获得

https://www.sec.gov/ix?doc=/Archives/edgar/data/1321732/000132173225000101/pen-20250822.htm

)

. To the extent holdings of Penumbra securities by the directors and executive officers of Penumbra have changed from the amounts of securities of Penumbra held by such persons as reflected therein, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC..

董事和高级管理人员持有的Penumbra证券数量如其中反映的有所变化，这些变化已或将在提交给美国证券交易委员会的表格4的所有权变动声明中反映出来。

CONTACTS

联系人

Boston Scientific:

波士顿科学：

Laura Aumann

劳拉·奥曼

Media Relations

媒体关系

+1 (651) 582-4251

laura.aumann@bsci.com

劳拉·奥曼@bsci.com

Lauren Tengler

劳伦·滕格勒

Investor Relations

投资者关系

+1 (508) 683-4479

BSXInvestorRelations@bsci.com

Penumbra:

半影:

Jennifer Heth

詹妮弗·赫斯

Media Relations

媒体关系

+1 (510) 995-9791

jheth@penumbrainc.com

杰思@彭姆布雷因克.康

Jason Mills

杰森·米尔斯

Investor Relations

投资者关系

+1 (925) 826-7933

jmills1@penumbrainc.com

我

Enterprise value based on 39.2 million common shares outstanding and vesting of shares under Penumbra's equity incentive plans for a total fully diluted share count of approximately 40.0 million shares, implying

基于3920万股流通普通股和Penumbra股权激励计划下股份的授予，企业价值完全稀释后的总股数约为4000万股，意味着

$15 billion

150亿美元

for 100% of the fully diluted equity, minus approximately

对于完全稀释后的100%股权，减去大约

$470 million

4.7亿美元

net cash and short-term investments as of

截至的净现金和短期投资

September 30, 2025

2025年9月30日

。